Search

Your search keyword '"Fritz, G"' showing total 3,356 results

Search Constraints

Start Over You searched for: Author "Fritz, G" Remove constraint Author: "Fritz, G"
3,356 results on '"Fritz, G"'

Search Results

2. GIPC1 regulates MACC1-driven metastasis

3. Activity of eftozanermin alfa plus venetoclax in preclinical models and patients with acute myeloid leukemia

5. Lack of the Ig cell adhesion molecule BT-IgSF (IgSF11) induced behavioral changes in the open maze, water maze and resident intruder test.

6. Discovery of Potent Azetidine-Benzoxazole MerTK Inhibitors with In VivoTarget Engagement

7. Discovery of A-910, a Highly Potent and Orally Bioavailable Dual MerTK/Axl-Selective Tyrosine Kinase Inhibitor

10. Abstract No. 270 Effectiveness of Chemical Component Separation Using Computed Tomography-Guided OnabotulinumtoxinA Injection in Postoperative Recurrence of Large Complex Ventral Abdominal Hernias: A Propensity Score-Weighted Analysis

13. The IgCAM CAR Regulates Gap Junction-Mediated Coupling on Embryonic Cardiomyocytes and Affects Their Beating Frequency

14. GIPC1 regulates MACC1-driven metastasis

16. Activity of eftozanermin alfa plus venetoclax in preclinical models and patients with acute myeloid leukemia

17. The multi-component field topology of sunspot penumbrae - A diagnostic tool for spectropolarimetric measurements

21. Around Crawford

22. The Joint astrophysical Plasmadynamic EXperiment (J-PEX): A high-resolution rocket spectrometer

23. High-Resolution Spectroscopy of G191-B2B in the Extreme Ultraviolet

24. USA Observation of Spectral and Timing Evolution During the 2000 Outburst of XTE J1550-564

25. USA and RXTE Observations of a Variable Low-Frequency QPO in XTE J1118+480

26. Early-Life Stress Regulates Cardiac Development through an IL-4-Glucocorticoid Signaling Balance

27. The USA X-ray Timing Experiment

34. Abstracts from the 8th International Conference on cGMP Generators, Effectors and Therapeutic Implications

37. Data from ABT-414, an Antibody–Drug Conjugate Targeting a Tumor-Selective EGFR Epitope

38. Figure S1 from Characterization of ABBV-221, a Tumor-Selective EGFR-Targeting Antibody Drug Conjugate

39. Data from Characterization of ABBV-221, a Tumor-Selective EGFR-Targeting Antibody Drug Conjugate

40. Supplementary Table 1, Table 2; Supplementary Figure 1 from ABT-414, an Antibody–Drug Conjugate Targeting a Tumor-Selective EGFR Epitope

43. Data from ABT-414, an Antibody–Drug Conjugate Targeting a Tumor-Selective EGFR Epitope

44. Figure S1 from Characterization of ABBV-221, a Tumor-Selective EGFR-Targeting Antibody Drug Conjugate

45. Supplementary Table 1, Table 2; Supplementary Figure 1 from ABT-414, an Antibody–Drug Conjugate Targeting a Tumor-Selective EGFR Epitope

46. Data from Characterization of ABBV-221, a Tumor-Selective EGFR-Targeting Antibody Drug Conjugate

49. Supplementary Data from Hexavalent TRAIL Fusion Protein Eftozanermin Alfa Optimally Clusters Apoptosis-Inducing TRAIL Receptors to Induce On-Target Antitumor Activity in Solid Tumors

50. Data from Hexavalent TRAIL Fusion Protein Eftozanermin Alfa Optimally Clusters Apoptosis-Inducing TRAIL Receptors to Induce On-Target Antitumor Activity in Solid Tumors

Catalog

Books, media, physical & digital resources